BioMarin to take Phase III hemophilia gene therapy data to regulators, announce filing timeline later this year
An analyst wrote that while the Phase III data - released alongside Phase I/II data - for valrox could be enough for accelerated FDA approval and appeared to allay concerns about declining Factor VIII levels, it could face commercial challenges.